Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys751Gln, in breast cancer

被引:0
|
作者
Noel Pabalan
Ofelia Francisco-Pabalan
Lillian Sung
Hamdi Jarjanazi
Hilmi Ozcelik
机构
[1] Saint Louis University,College of Natural Sciences
[2] University Health Network,Analytical Genetics Technology Centre, Princess Margaret Hospital
[3] Hospital for Sick Children,Division of Hematology/Oncology
[4] Ontario Ministry of the Environment,Environmental Monitoring and Reporting Branch
[5] Mount Sinai Hospital,Fred A. Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute
来源
Breast Cancer Research and Treatment | 2010年 / 124卷
关键词
Breast cancer; ERCC2; XPD; Asp312Asn; Lys751Gln; Adducts;
D O I
暂无
中图分类号
学科分类号
摘要
The excision repair cross-complementing group 2 gene (ERCC2) plays a key role in DNA repair. Several polymorphisms in the ERCC2 gene have been described, including the commonly occurring Lys751Gln and Asp312Asn polymorphisms. Studies investigating the association of these polymorphisms with breast cancer risk produced controversial results. To evaluate these associations presented in diverse populations, we have conducted a meta-analysis based on 40 studies from 33 publications in PubMed which included analyses of Lys751Gln (14,545 cases, 15,352 controls) and Asp312Asn polymorphisms (16,254 cases, 14,006 controls). Overall findings of both polymorphisms have implicated null effects (OR = 1.01–1.03) when the analyses were limited to the statistically powerful (≥80%) studies. Although modestly increased statistically significant breast cancer risk was detected in the underpowered studies (≤80%), removal of outliers resulted in null associations. Ethnic stratification showed non-significant and relatively null associations for both polymorphisms with breast cancer risk for the overall Caucasians as well as North American and the European sub-populations. Although statistically increased and decreased risks were observed for the homogenous populations of African-Americans (Lys751Gln, OR 1.25, 95% CI 1.03–1.53, P = 0.03) and Asians (Asp312Asn, ORs: 0.53–0.55, P values: 0.02–0.03), respectively, this may be the result of small sample size. Analyses of the homogeneous adduct studies, with relatively large sample size, exhibited increased risk for Lys751Gln (OR 1.20, 95% CI (1.02–1.41), P = 0.03) and Asp312Asn (OR 1.17 95% CI 1.02–1.34, P = 0.03) under the dominant genetic model. In conclusion, our results suggest null associations of both polymorphisms in the overall and the Caucasian subgroups, although some effects can be suggested for relatively smaller minority studies. Increased risk effect was more visible when the adduct studies are considered, suggesting the role of these polymorphisms in the presence of exposure to DNA damaging agents.
引用
收藏
页码:531 / 541
页数:10
相关论文
共 50 条
  • [21] XPD Lys751Gln polymorphism and breast cancer susceptibility: a meta-analysis involving 28,709 subjects
    Li-Xin Qiu
    Lei Yao
    Jian Zhang
    Xiao-Dong Zhu
    Xin-Min Zhao
    Kai Xue
    Chen Mao
    Bo Chen
    Ping Zhan
    Hui Yuan
    Xi-Chun Hu
    Breast Cancer Research and Treatment, 2010, 124 : 229 - 235
  • [22] ERCC2 Lys751Gln polymorphism is associated with lung cancer among Caucasians
    Zhang, Jian
    Gu, Shi-Yang
    Zhang, Ping
    Jia, Zhen
    Chang, Jian-Hua
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (13) : 2479 - 2484
  • [23] The association between ERCC2 Asp312Asn polymorphism and breast cancer risk: a meta-analysis involving 22,766 subjects
    Lei Yao
    Li-Xin Qiu
    Lu Yu
    Zhen Yang
    Xia-Jia Yu
    Yang Zhong
    Xi-Chun Hu
    Long Yu
    Breast Cancer Research and Treatment, 2010, 123 : 227 - 231
  • [24] Association Between XPD Asp312Asn Polymorphism and Esophageal Cancer Susceptibility: A Meta-analysis
    Duan, Xiao-Li
    Gong, Heng
    Zeng, Xian-Tao
    Ni, Xiao-Bing
    Yan, Yan
    Chen, Wen
    Liu, Guo-Lei
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (07) : 3299 - 3303
  • [25] Association between XPD Lys751Gln polymorphism and risk of head and neck cancer: a meta-analysis
    Yuan, H.
    Niu, Y. M.
    Wang, R. X.
    Li, H. Z.
    Chen, N.
    GENETICS AND MOLECULAR RESEARCH, 2011, 10 (04) : 3356 - 3364
  • [26] XPD Lys751Gln polymorphism and esophageal cancer susceptibility: a meta-analysis of case–control studies
    Da-Peng Ding
    Wen-Li Ma
    Xiao-Feng He
    Ying Zhang
    Molecular Biology Reports, 2012, 39 : 2533 - 2540
  • [27] XPD Lys751Gln polymorphism is not associated with oral cancer risk: evidence from a meta-analysis
    Cui, Jing
    Li, Dalu
    Shen, Liang
    Zhang, Wenmei
    Xu, Xin
    TUMOR BIOLOGY, 2014, 35 (07) : 6335 - 6341
  • [28] Association between ERCC2 Lys751Gln polymorphism and the risk of pancreatic cancer, especially among Asians: evidence from a meta-analysis
    Wu, Yang
    Lu, Zi-Peng
    Zhang, Jing-Jing
    Liu, Dong-Fang
    Shi, Guo-Dong
    Zhang, Chun
    Qin, Zhi-Qiang
    Zhang, Jian-Zhong
    He, Yuan
    Wu, Peng-Fei
    Miao, Yi
    Jiang, Kui-Rong
    ONCOTARGET, 2017, 8 (30) : 50124 - 50132
  • [29] Lys751Gln polymorphism in ERCC2 gene is associated with lung cancer susceptibility in the Chinese population
    Liang, Geyu
    Pu, Yuepu
    Yin, Lihong
    PROGRESS IN NATURAL SCIENCE-MATERIALS INTERNATIONAL, 2007, 17 (07) : 872 - 876
  • [30] Association between the XPD/ERCC2 Lys751Gln polymorphism and risk of cancer: evidence from 224 case-control studies
    Wu, Kai-Ge
    He, Xiao-Feng
    Li, Yun-Hui
    Xie, Wei-Bin
    Huang, Xi
    TUMOR BIOLOGY, 2014, 35 (11) : 11243 - 11259